The disease burden due to nontuberculous mycobacteria is growing worldwide, consequently to improved diagnostic abilities and an increase in the individuals at risk. Uncertainties exist about the right moment on which start treatment. We investigated the clinical features associated with starting an antimicrobial treatment in patients with nontuberculous mycobacterial lung disease among Italian physicians involved in the field. We found that in real life predictors of starting antimicrobial treatment are quite adherent to international guidelines, with some uncertainties regarding the implication of immunosuppressive drugs.
Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: a SITA GIOVANI-IRENE promoted web-survey / A. Lombardi, M. Colaneri, M. Sambo, A. Di Matteo, P. Sacchi, M. Fabbiani, L. Codecasa, S. Aliberti, F.B.A. Blasi, A. Bandera, R. Bruno, A. Gori. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - (2021). [Epub ahead of print] [10.1016/j.rmed.2021.106341]
Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: a SITA GIOVANI-IRENE promoted web-survey
A. Lombardi
;M. Colaneri;S. Aliberti;F.B.A. Blasi;A. Bandera;A. GoriUltimo
2021
Abstract
The disease burden due to nontuberculous mycobacteria is growing worldwide, consequently to improved diagnostic abilities and an increase in the individuals at risk. Uncertainties exist about the right moment on which start treatment. We investigated the clinical features associated with starting an antimicrobial treatment in patients with nontuberculous mycobacterial lung disease among Italian physicians involved in the field. We found that in real life predictors of starting antimicrobial treatment are quite adherent to international guidelines, with some uncertainties regarding the implication of immunosuppressive drugs.File | Dimensione | Formato | |
---|---|---|---|
predictors of starting antimicrobial treatment in patients with NTM lung diseases Resp Med 2021.pdf
Open Access dal 15/02/2022
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
415.64 kB
Formato
Adobe PDF
|
415.64 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.